Towards Health & Prosperity… An Update on an Action Plan to Help Attract More Clinical Trials to Canada (December 2012)
On the first anniversary of the 2011 Clinical Trials Summit, ACAHO, Rx&D, and CIHR reflect on the year since the 2011 Summit and give a six-month progress report since the Action Plan’s release. Author/Presenter: Rx&D, CIHR, ACAHO
To Your Health & Prosperity – An Action Plan to Help Attract More Clinical Trials to Canada (March 30, 2012)
Action plan from the 2011 National Clinical Trials Summit. It is the third and final paper in a trilogy of papers from the clinical trial summit hosted by Rx&D, CIHR, and ACAHO.
Proceedings & Implications from the 2011 Clinical Trials Summit: Towards an Action Plan (with Appendix reflecting Feedback from Request to Reader)
This is the second in a trilogy of papers from the September 2011 Clinical Trials Summit hosted by Rx&D, CIHR and ACAHO. Author/Presenter: RX&D, CIHR, ACAHO
Background Document – Starting the Conversation
Background document prepared for the 2011 National Clinical Trial Summit. Author/Presenter: RX&D, CIHR, ACAHO
Strategic Infrastructure Issues 2
A discussion of international clinical trial infrastructure models and what is necessary to improve Canada’s competitiveness in clinical research. Author/Presenter: Dr. Jean-Marie Leclerc, Chief Scientific Officer and Senior Vice President, Clinical and Regulatory Affairs, Novartis
Strategic Infrastructure Issues 1
A discussion of international clinical trial infrastructure models and what is necessary to improve Canada’s competitiveness in clinical research. Author/Presenter: Dr. Rob McMaster, Vice President Research, Vancouver Coastal Health
Cost Issues
Presentation by L. Bennett, and Dr. S. Choudhri at the 2011 National Clinical Trials Summit on Cost Structure. Author/Presenter: Linda Bennett, Executive Director, Canadian Rheumatology Research Consortium & Dr. Shurjeel Choudhri, Senior Vice-President and Head, Medical and Scientific Affairs, Bayer Inc.
Admininstrative Issues
Presentation by Dr. N. Maresky & K. Arts at the 2011 National Clinical Trials Summit on Improving Administrative Aspects of the Canadian Clinical Trials Environment. Author/Presenter: Dr. Neil Maresky, Vice-President, Scientific Affairs, AstraZeneca Inc. & Karen Arts, Director, Business Development, Clinical Trials, Ontario Institute for Cancer Research & Co-Founder and Chair of Board of Directors […]
Recruitment & Retention
Presentation by D. Simmons & S. Gazel at the 2011 National Clinical Trials Summit on Patient Recruitment Retention and Follow-up Author/Presenter: Diane Simmons, President and CEO, Center for Information and Study on Clinical Research Participation & Sandra Gazel, Associate Director, Clinical Operations, Abbott
Streamlining Ethics Review
Presentation by L. Barrett-Smith & Dr. S. Glezer at the 2011 National Clinical Trials Summit on Streamlining Ethics Review in Canada, titled: A matter of Balance Author/Presenter: Linda Barrett-Smith, Drector, Research Ethics & Alberta Clinical Research Consortium (ACRC) & Dr. Stanislav Glezer, Vice-President Medical Affairs, Sanofi-Aventis
Summary, Implications and Next Steps
Keynote address by Dr. A. Slutsky at the 2011 National Clinical Trials Summit titled: Starting the Conversation…A SWOT, So What, & Now What? Summary, Implications & Next Steps Author/Presenter: Dr. Arthur Slutsky, ACAHO Research Co-Chair & Vice President Research, St. Michael’s Hospital
Matrix on current initiatives in Canada
Keynote address by Dr. J. Rouleau at the 2011 National Clinical Trials Summit titled: SPOR: A Major Strategy for the Development of Clinical Research in Canada Author/Presenter: Dr. Jean Rouleau, Scientific Director, CIHR Institute of Circulatory and Respiratory Health
Globalization of clinical research & metrics survey results
Keynote address by N. Laberge at the 2011 National Clinical Trials Summit titled: Globalization of Clinical Research: Trends & Implications for Canada Author/Presenter: Normand Laberge, Vice-President, Regulatory and Scientific Affairs, Canada’s Research-based Pharmaceutical Companies (Rx&D)
Opening Remarks – ACAHO
Opening Remarks by G. Brimacombe, President & CEO of ACAHO at the 2011 Clinical Trials Summit Author/Presenter: Mr. Glenn Brimacombe, President & CEO, ACAHO
Opening Remarks
Opening Remarks by R. Williams, President of Rx&D at the 2011 National Clinical Trials Summit. Author/Presenter: Russell Williams, President, Canada’s Research-Based Pharmaceutical Companies (Rx&D)
Canadian Clinical Trial Summit – Starting the Conversation (September 15, 2011)
On September 15, 2011, ACAHO, Canada’s Research-Based Pharmaceutical Companies (Rx&D) and the Canadian Institutes of Health Research (CIHR) co-hosted a National Clinical Trial Summit designed to help reinvigorate and re-establish Canada’s tradition of excellence in clinical trials, bringing together over 120 experts from patient care sites, research, academia, government and industry in a first time […]
Investment Case – “Clinical Trials – The Canadian Advantage” – 2018
The case for running clinical trials in Canada, advantages and information (English, pdf format) Author/Presenter: CCTCC
Investment Case – “Clinical Trials – The Canadian Advantage” – 2018 – French
The case for running clinical trials in Canada, advantages and information (French, ppt format) Author/Presenter: CCTCC https://www.cctcc.ca/wp-content/uploads/2018/08/CCTCC_InvestmentCase_Updated-June-2018_French.pptx
Investment Case – “Clinical Trials – The Canadian Advantage” – 2018 – French
The case for running clinical trials in Canada, advantages and information (French, pdf format) Author/Presenter: CCTCC
Investment Case – “Clinical Trials – The Canadian Advantage” – 2018
The case for running clinical trials in Canada, advantages and information (English, ppt format) Author/Presenter: CCTCC https://www.cctcc.ca/wp-content/uploads/2018/02/CCTCC_CT-Investment-Case_June-2017_Final1.pptx
2018 Strategic Planning Report: A pan-Canadian Clinical Trial Strategy
Report and Key Result areas from the Strategic Planning process initiated in 2017 and facilitated by Intersol. Author/Presenter: CCTCC/Intersol
Proposed Data Collection for mCTA metrics draft
Proposed metrics on the usage of the mCTA Author/Presenter: CCTCC https://www.cctcc.ca/wp-content/uploads/2018/08/Proposed-Data-collection-for-mCTA-metrics-draft.xlsx
The CCTCC 2014-2017 Report to Stakeholders
Author/Presenter: CCTCC
Determining Canada’s needs for a pan-Canadian Clinical Trials Organization
Report from the Strategic Planning Workshop, June 28, 2017, Toronto, ON Author/Presenter: CCTCC/Intersol
Advancing the mCTA through collaboration with the CLEAR initiative (TransCelerate-supported project)
Results of the 2016 mCTA Consultation and Open Houses for Sponsors and release of mCTA version 8.0 Author/Presenter: CCTCC
mCTA version 8 use letter final
Letter template for sites and sponsors to confirm their adoption of the mCTA Author/Presenter: CCTCC https://www.cctcc.ca/wp-content/uploads/2018/08/mCTA-version-8-use-letter-final-draft.docx
mCTA_Version 8_PP Slides (pp)
Informational slides on the history and use of the mCTA (powerpoint format) Author/Presenter: CCTCC https://www.cctcc.ca/wp-content/uploads/2018/08/mCTA_Version-8_PP-Slides.pptx
mCTA_Version 8_PP Slides (pdf)
Informational slides on the history and use of the mCTA (pdf format) Author/Presenter: CCTCC
mCTA Version 8_Final_June 2017 (pdf)
Version 8 of the mCTA contract (pdf format) Author/Presenter: CCTCC
mCTA Version 8_Final_June 2017 (Word)
Version 8 of the mCTA contract (Word format) Author/Presenter: CCTCC https://www.cctcc.ca/wp-content/uploads/2018/08/mCTA-Version-8_Final_June-2017.docx
Drivers for the FMV Initiative (Sites)
Presentation of key drivers for the Fair Market Value initiative from the site perspective Author/Presenter: CCTCC
CCTCC & Health Canada Response to REB WG Final Recommendations
Joint response by the CCTCC and Health Canada to the final recommendations of the CCTCC REB Accreditation WG Author/Presenter: CCTCC & Health Canada
CCTCC & Provincial Clinical Trials Organizations’ Meeting – November 2016
Meeting package from the November 2016 Meeting of the Provincial Clinical Trial Organizations Author/Presenter: CCTCC
CCTCC REB Accreditation WG Final Recommendations
The final report and recommendations of the CCTCC REB Accreditation WG established in April 2015 Author/Presenter: CCTCC REB Accreditation Working Group
CCTCC & Provincial Clinical Trials Organizations’ Meeting – April 2016
Meeting package from the April 2016 Meeting of the Provincial Clinical Trial Organizations Author/Presenter: CCTCC
REB Accreditation WG Interim Report
The interim report of the CCTCC REB Accreditation WG established in April 2015 Author/Presenter: CCTCC REB Accreditation Working Group
Clinical trials transparency in the Americas: the need to coordinate regulatory spheres
BMJ 2018; 362:k2493 Author/Presenter: Trudo Lemmens, professor and Scholl chair in health law and policy, and Carlos Herrera Vacaflor, researcher
Canada’s Clinical Research Community Needs Public Input
Press Release – BCCRIN-N2-CCTCC-National Survey Author/Presenter: BCCRIN, N2 & CCTCC
Health Canada’s new clinical trials database should be mandatory, says expert
CMAJ, August 6, 2013, 185(11) Author/presenter: Miriam Shuchman
How does Canada’s clinical trials database Measure Up?
Article in Macleans on what the Health Canada clinical trials database means for health transparency Author/presenter: Julia Belluz, Senior Editor, Medical Post
Trials and tribulations: As a declining share of global clinical trials threatens the future of health research in Canada, a national collaborative effort is underway to reverse the slide
Healthcare Research and Innovation Winter 2012, Canadian Healthcare Network Author/Presenter: Joe McAllister
Boilerplate being tested for clinical trials agreements
CMAJ November 08, 2011 183 (16) Author/Presenter: Lauren Vogel
Game Changers: Does Canada Have a Place on the Clinical Trial Podium?
Canada’s Innovation Leaders, a RE$EARCH Infosource Inc. Publication Author/Presenter: W. Robert McMaster – Executive Director Vancouver Coastal Health Research
News Release – Clinical Trials Summit – EN
News Release on the occasion of the 2011 National Clinical Trials Summit Author/Presenter: Rx&D, CIHR, ACAHO
Clinical trials: the muddled Canadian landscape
CMAJ January 6, 2009 180(1) Author/Presenter: Ann Silversides, CMAJ
Initiatives for enhancing the Canadian Clinical Research Environment
RDC Webinar Presentation Author/Presenter: Kathryn Nijssen, Initiatives Manager, CCTCC
Enhancing the Canadian Clinical Research Environment – The mCTA and Fair Market Value Initiatives
CARA East 2017 Breakout Session Presentation Author/Presenter: Kathryn Nijssen, Initiative Manager, CCTCC and Dex Bilkic, Manager, Study Start-Up & Patient Recruitment, Bayer Canada
Canadian Clinical Trials Coordinating Centre (CCTCC)
Presentation by the CCTCC to the Huntington’s Society on current initiatives Author/Presenter: Elena Aminkova
Canadian Clinical Trials Coordinating Centre (CCTCC)
Presentation by the CCTCC to SOCRA on current initiatives Author/Presenter: Elena Aminkova
16th Clinical Trials in Canada Summit October 5_2016
Presentation by Elena Aminkova at 16th Clinical Trials in Canada Summit 2016 Author/Presenter: Elena Aminkova, CCTCC
Initiatives for Enhancing the Canadian Clinical Research Environment
Presentation by Dr. Shurjeel Choudhri at the 2016 Evolution Summit Author/Presenter: Dr. Shurjeel Choudhri, Senior Vice President & Head, Medical and Scientific Affairs, Bayer Inc. Chair, Executive Committee, CCTCC
“Clinical Trials – The Canadian Advantage” panel
Bio 2016 Panel Discussion, San Francisco, CA Author/Presenter: CCTCC, Panel Moderated by Mr. Michel Perron – Vice-President, External Affairs and Business Development, CIHR
Strengthening Clinical Trials for Canadians: An Update on the Canadian Clinical Trials Coordinating Centre
Presentation by the CCTCC at the 2015 CAREB Conference Author/Presenter: Belinda Vandersluis
Canada’s Cost and Tax Advantages – Clinical Trials
Invest in Canada Factsheet Clinical Trials 2017 Author/Presenter: Invest in Canada
Investment Case on the Value of Conducting Clinical Trials in Canada
Author/Presenter: Department of Foreign Affairs, Trade and Development & CCTCC Prepared by IMS Brogan
Canada : A World Leading Location to Conduct Clinical Trials
Department of Foreign Affairs, Trade and Development (DFATD) Prepared by IMS Brogan
SPOR SHRER Report Appendix E Development of Forms
SPOR SHRER Report and Appendix E Development of Forms Author/Presenter: CIHR SPOR
SPOR SHRER Report Appendix D
SPOR SHRER Report Appendix D Harmonization Survey Author/Presenter: CIHR SPOR
SPOR SHRER REPORT Appendix C
SPOR SHRER Report Appendix C_1-C_2 Model Elements CT Forms Author/Presenter: CIHR SPOR
SPOR SHRER Report and Appendices A & B
SPOR SHRER Report and Appendices A & B Author/Presenter: CIHR SPOR
Senate of Canada
The Standing Senate Committee on Social Affairs, Science and Technology, November (2012) regarding the state of Clinical Trials in Canada. Author/Presenter: Standing Senate Committee on Social Affairs, Science and Technology – The Honourable Kelvin K. Ogilvie, Chair & The Honourable Art Eggleton, P.C., Deputy Chair
The Advantages of Doing Research in Canada – A Summary of Research and Development Tax incentives
R&D Tax Credits summary published by Invest in Canada Bureau in 2007 Author/Presenter: Invest in Canada Bureau, in consultation with Canada’s Revenue Agency. Initially developed by the S&T Team of the Berlin Canadian Embassy https://www.cctcc.ca/wp-content/uploads/2018/08/advantages.of_.doing_.RD_.in_.canada-2007.pdf